Agomab Therapeutics NV Adrs AGMB

$5.62 -0.20 (-3.44%)

Valuation

Market cap
214,523,000
Revenue TTM
$0
Net income TTM
$-70,770,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
335,800
Avg volume
209,654
Day's range
$5.59 – $6.00
Shares out
36,237,000
Stochastic %K
12%
Beta
—
Analysts
Strong Buy
Price target
$37.67

Price

Company profile

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-44...

Show more

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Industry
Biotechnology
Sector
Healthcare
Phone
32 3 318 91 70
Website
https://www.agomab.com
Address
Posthoflei 1/6, Antwerp, Belgium

Latest news

Stocktwits

caracicatriz Nov 16, 9:01 PM
$AGMB $PFE has increased its stake in $AGMB to 5%. I smell an acquisition attempt in the near future given the great Phase 2a results and cash war chest
2 replies
Bankpas Nov 16, 6:50 PM
$AGMB come on, give them some love…insiders keep buying!
0 replies
FilingTracker Nov 16, 11:44 AM
$AGMB Insider purchase: https://filingtracker.ai/filing/1445826/0001445826-26-000019?doc=primary_doc.xml
0 replies
Jupilerke Nov 9, 9:28 PM
$AGMB Volume picking up? 🤫
1 replies
GTA_Terminal Nov 9, 12:36 PM
Unusual options activity in $AGMB. Both sides are getting paid for here. Somebody expects a move, they just don't agree which way. Read the full article for the full details: https://globaltradersacademy.com/articles/agomab-agmb-technical-levels-options-flow-mixed-between-6-46-and-8-15?utm_source=stocktwits&utm_medium=social
0 replies
LewisDaKat Nov 4, 9:30 PM
$AGMB Agomab to Participate in Upcoming Investor Conferences https://marketwirenews.com/stock/agmb/news/agomab-to-participate-in-upcoming-investor-conferenc-7597824636915289.html?utm_source=stocktwits
0 replies
Achouffe Oct 16, 12:08 PM
Took a first position in $AGMB at $8,2. In sympathy with the CEO 😀 and I hope we don't lose any finger(s)
0 replies
filecrux Oct 13, 9:46 PM
$AGMB Belgian fibro-inflammation biotech Agomab dosed the first patient in its ~320-patient Phase 2b of ontunisertib in fibrostenosing Crohn's, triggering a €7M payment to former Origo Biopharma holders. The €7M is about 2.8% of the €252.0 million in cash, cash equivalents and short-term cash investments Agomab held at June 30, 2026, which the company expects to fund operations into the first half of 2029. Payable so far: €10M of up to €20M; the rest needs further development and regulatory steps. Primary endpoint at Week 24; no readout date given.
0 replies